Masahiro Kamata
40PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (40)
Sort by Publication Date:
|Mar 08, 2026
A 308-nm Excimer Lamp Ameliorates MC903-Induced Atopic Dermatitis With Reductions of Intraepidermal Nerve Fiber Density and Expression of Thymic Stromal Lymphopoietin.Thalita Bastos, Makoto Ito, Masahiro Kamata
|Oct 25, 2025
Combined Maxacalcitol/Betamethasone Butyrate Propionate Ointment Possesses Long-Term Sustained Effects of Inducing Regulatory T Cells and Downregulating the Th17 Response, Even After Discontinuation of Its Application in Imiquimod-Induced Psoriasiform Dermatitis.Teruo Shimizu, Masahiro Kamata, Hideya Uratsuji
|Nov 02, 2024
Real-World Experience of 3-Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis.Hideyuki Nakajima, Masahiro Kamata, Yoshiki Okada
|Oct 21, 2024
Serum interleukin-10 level is increased and correlated positively with disease severity in patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.Shoya Suzuki, Masahiro Kamata, Hideaki Uchida
|Sep 15, 2024
Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world.Ayu Watanabe, Masahiro Kamata, Yoshiki Okada
|May 28, 2024
Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors.Ryosuke Takeshima, Masahiro Kamata, Shoya Suzuki
Pageof 7